The use of blockers of the renin-angiotensin system (RAS blockers) as antihypertensive and antiproteinuric medication has been particularly effective in slowing the progression of renal disease in type 2 diabetics [60], and all existing guidelines advise to introduce an angiotensin converting enzymes inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) in diabetic patients with CKD, as soon as microalbuminuria is detected or in case of hypertension [61]. Here, REN is linked to hypertensive disorder.